XOMA News and Press, XOMA Corporation From 11/04/21

EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 development stage, triggering a $35 million milestone payment from Novartis.  The...

Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of pancreatic cancer DAY101 received Rare Pediatric Disease Designation for ...

EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT. About XOMA Corporation ...

EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23 rd Annual Global Investment Virtual Conference held on September 13-15, 2021.  The presentation will ...

Half of my retirement savings is invested in two sectors. It's important to match your investment allocations to what will meet your goals and needs. Income investing provides extremely high levels of flexibility. For further details see: I Put Half Of My Retirement Savi...

Unlike other players in its space, biotech royalty aggregator XOMA Corporation (XOMA) focuses on early and mid-stage assets requiring smaller capital commitments. Since the company’s pivot to royalty aggregation in 2017, it has accumulated over 70 programs, yet none have reache...

EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the Company’s Board of Directors. Ms. Franklin has significant experience in corporat...

Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the tre...

syahrir maulana/iStock via Getty Images XOMA (XOMA) announces that NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. FDA. NIS793 is a potential first in class novel antibody specific for Transforming Growth Facto...

EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.  NIS793 is a potential...